Review

IBD metabonomics predicts phenotype, disease course, and treatment response

Jacob T. Bjerrum, Yulan L. Wang, Jakob B. Seidelin, Ole H. Nielsen

Abstract

Metabonomics in inflammatory bowel disease (IBD) characterizes the effector molecules of biological systems and thus aims to describe the molecular phenotype, generate insight into the pathology, and predict disease course and response to treatment. Nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and integrated NMR and MS platforms coupled with multivariate analyses have been applied to create such metabolic profiles. Recent advances have identified quiescent ulcerative colitis as a distinct molecular phenotype and demonstrated metabonomics as a promising clinical tool for predicting relapse and response to treatment with biologics as well as fecal microbiome transplantation, thus facilitating much needed precision medicine. However, understanding this complex research field and how it translates into clinical settings is a challenge. This review aims to describe the current workflow, analytical strategies, and associated bioinformatics, and translate current IBD metabonomic knowledge into new potential clinically applicable treatment strategies, and outline future key translational perspectives.

1. Introduction

Inflammatory bowel disease (IBD) is a condition of recurrent or chronic intestinal inflammation giving rise to diarrhea, bloody stools, abdominal discomfort, and anorexia. IBD is a global disease with increasing incidence in developing and Westernized countries, although a plateau seems to have been reached in high-income countries [1]. IBD is believed to be a multifactorial disease and the consequence of a disturbed immunologic response to environmental and microbial components in genetically susceptible individuals [2]. Ulcerative colitis (UC) [3] and Crohn's disease (CD) [4] are the two main entities of IBD, and although they share a range of characteristics, they are two distinct diseases requiring exact differentiation and phenotyping for tailored treatment and precision medicine [5]. Predicting disease course and treatment response is the very essence of precision medicine but also a challenging task because the dissection of genotype-to-phenotype relations is not straightforward owing to the wide range of downstream regulatory processes that take place from the genome to the metabolome and the concomitant interactions with the exposome and microbiome (Fig. 1A). Thus, the complexity of the network increases toward the metabolome, which is the entire set of intermediates and end products of metabolism, that is, the life-sustaining chemical processes of the biological system. The metabolome is accordingly highly reflective of the actual (patho-)physiologic phenotype and can be characterized by metabolic profiling, or metabonomics, which is the study of metabolic changes in response to internal and external stimuli in an integrated biological system [6]. Metabonomics is used interchangeably with metabolomics, however, metabolomics aims to characterize and quantify all the small molecules in complex biological samples, whereas, metabonomics aims to measure the global, dynamic metabolic response of living systems to biological stimuli or disease. Metabonomics consequently focus on understanding systemic changes through time in complex multicellular systems, which is in line with most studies performed within the field of IBD. Nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS) are usually applied in IBD metabonomic studies to generate extensive targeted or untargeted metabolic profiles. These complex, multivariate data subsequently need to be coupled with bioinformatic tools to extract meaningful information. The ongoing development of metabolomic technologies and advances in bioinformatics have resulted in a steady increase in more sophisticated IBD studies over the past two decades. Recent excellent reviews provide comprehensive and descriptive overviews of currently available IBD metabonomic studies in relation to the microbiome [7], volatome [8], sample type [9], and metabolites [10] by addressing the contribution of the metabolome to the IBD pathogenesis, but one of the major challenges is to translate these
findings into new tools of clinical relevance. The vast majority of IBD metabonomic studies focus on IBD diagnostics and differentiation between UC and CD [11–17], and this has resulted in conflicting outcomes because apparent diagnostic and differential power seems to be lost once the metabonomic data are corrected for potential confounders such as surgery and medication [14]. A more consistent finding is the identification of quiescent UC as a distinct metabonomic phenotype compared with patients with active disease and healthy control individuals [18–21]. Furthermore, recent studies have also demonstrated metabonomics as a potential clinical tool for predicting relapse [22] and response to treatment with biologics [23] as well as fecal microbiome transplantation (FMT) [24], thus facilitating proactive medical care.

With these recent promising studies within the field of IBD metabonomics the objective of this review is to provide an up-to-date overview of currently available analytical technologies and their associated applicability in metabonomic studies; to introduce human IBD metabonomic studies as a tool for molecular phenotyping, prediction of disease course, and treatment response; and finally, to outline future perspectives of importance in the field. This review consequently highlights the importance of metabonomics as an essential tool for the development of future personalized medicine.

2. Commonly applied workflow, analytical strategies, and multivariate analyses

The total estimated number of endogenous human metabolites is approximately 6,500 [25]. However, because the metabolome is the most downstream of omics from drugs, ingested food, and their metabolites, as well as metabolites generated from the interactions between human and symbiotic gut microbiota, the number of metabolites potentially exceeds ~100,000 [26]. The concentrations of these metabolites range from micromole to millimole (e.g., amino acids and tricarboxylic acid [TCA] cycle intermediates) and from picomole to femtomole (e.g., hormones). The vast number of metabolites with different chemical and physical properties and large dynamic ranges makes the identification and quantification of metabolites challenging tasks, especially because they also need to be associated with disease perturbations such as IBD. Metabonomic studies consequently require large cohorts of patients with IBD and matched control individuals with carefully recorded demographics and clinical details, planning of the sampling type and often successive sampling to identify metabolic trajectories, as well as an integrated approach of different analytical platforms and subsequent carefully performed multivariate analyses (Fig. 1B) [27]. The analytical strategies applied depend on the scientific question because nuclear magnetic resonance spectroscopy (NMR)–based metabonomics is used to identify and semi-quantify metabolites in an untargeted approach (Fig. 2A), whereas mass spectrometry (MS) is ideal for absolute quantification (Fig. 2B and C).

2.1. Nuclear magnetic resonance spectroscopy

NMR employs 1H for the detection of metabolites because protons are the most abundant nuclei present in biological samples [28]. Because the intensity of the 1H NMR spectrum is directly proportional to the number of protons in a molecule, high-resolution NMR spectroscopy is able to quantify the metabolites in an untargeted approach. The resonance of a proton in an NMR spectrum represents its chemical environment and consequently carries molecular structural information that allows identification of the metabolites [28]. The NMR technique additionally permits spectral editing so that the different properties of the metabolite signals can be split up without separating the sample itself; spin-spin relaxation time–edited NMR spectra only carry information on mobile molecules, whereas diffusion-edited NMR spectra attenuate signals from smaller molecules and selectively display only bounded molecules such as lipoprotein lipids [29]. In addition, NMR-based metabonomics is a robust and reliable technique with high reproducibility that requires minimal or no sample preparation, is nondestructive, has a low running cost and high throughput, and is virtually the only technique able to analyze intact tissue [30]. However, NMR-based metabonomics suffers from low intrinsic sensitivity and heavy signal overlap [29]. Although an increasing number of scans and spectral editing/stable isotope labeling strategies to some extent ameliorate these drawbacks, the number of metabolites that can be detected is limited.

2.2. Mass spectrometry and integration with NMR spectroscopy

MS is another commonly applied technology for the investigation of metabonomics that is typically coupled with separation techniques such as liquid chromatography (LC), gas chromatography (GC), and capillary electrophoresis (CE) [31]. MS-based metabonomics can be divided into targeted and untargeted approaches. The targeted approach selectively quantifies specific metabolites, a class of metabolites, or metabolites in a pathway such as bile acids or amino-containing metabolites [32,33]. It requires the addition of internal standards for identification and quantification purposes. The advantage of this approach is that the MS conditions can be optimized for ideal separation and detection, resulting in identification of metabolites in the picomole range, but it requires a priori knowledge and valid hypotheses regarding the samples of interest. For discovery purposes, untargeted MS analysis is employed, which typically generates ~10,000 features depending on the profiling method and
analytical platform. The challenge associated with the untargeted approach is the identification of metabolites. The workflow involves conducting additional MS/MS fragmentation experiments for the unknown metabolites, putative metabolite identification by checking the fragmentation pattern against metabolite databases such as the Human Metabolome Database (HMDB) and Metlin (metabolite and chemical entity database), metabolite verification by spiking the standard compounds, and further quantification [34]. In case the standard molecule is unavailable, synthesis of the compound is necessary for final confirmation. Recently, a high coverage of metabolites employing pseudo-targeted profiling approaches has shown enhanced metabolite identification power, but the ability to discover new metabolites is still limited [35]. Compared with NMR-based metabonomics, the sensitivity of MS is superior [36]. However, more
care should be taken when conducting MS experiments because the reproducibility of MS is intrinsically low, and quality control strategies are necessary to obtain reproducible results. Because metabolites are complex and diverse with different chemical properties and concentrations, integrated NMR/MS-based analytical platforms and the combination of targeted and untargeted approaches are necessary. The choice of analytical platforms depends on the scientific questions asked and whether plausible hypotheses are available. An LC/MS-based targeted approach is the first choice when validating a hypothesis in which a known metabolite needs to be detected because an MS-based targeted approach has the most sensitivity. For exploratory purposes, NMR- and MS-based untargeted approaches can be combined for untargeted metabolic profiling studies.

Both ¹H NMR- and MS-based metabolomic studies contain high-density information, and series of multivariate statistical analyses such as principal component analysis (PCA), partial least squares/projections to latent structures discriminant analysis (PLS-DA), and orthogonal signal correction projections to latent structures discriminant analysis (O-PLS-DA) are often applied (Fig. 3; Box 1) [37,38]. These methods apply dimensional reduction strategies to complex spectral data in order to decode the changes relating to the biological perturbations of interest. However, despite the current technological and bioinformatic advances, it is essential to acknowledge the limitations of metabolomics, as none of the existing technologies can identify the entire metabolome. Furthermore, the metabolome is an ever-changing and dynamic structure due to the continuous influence of up-stream omics and the environment, and the results from metabolomics studies consequently need to be interpreted under these conditions and with caution.

3. Metabolomics characterizes IBD phenotypes

3.1. Metabolic remission and quiescent disease

Some of the earliest work in IBD metabolomics used NMR spectroscopy on colonic biopsies and differentiated between patients with active UC, patients with active CD, and control individuals with an impressive sensitivity and specificity ranging from 96% to 100% [18]. However, when colonic samples from patients with IBD and quiescent disease had to be validated in the established classifier, only 82% could be classified unambiguously, and 42% of those (primarily patients with UC) were assigned as abnormal or inflamed despite endoscopically and histologically confirmed quiescent disease [18]. This observation was substantiated in a methodologically similar study with NMR spectroscopy on colonic biopsies and isolated colonic mucocytes from UC patients and control individuals; patients with active UC and control individuals were easily differentiated, but 36% of endoscopically assessed quiescent UC patients were classified as inflamed [19]. These 36% were characterized by having a flare-up within 6 months either prior to or after sample collection. Sharma et al. [39] used paired colonic biopsies from uninvolved and involved colonic mucosa from the same UC patients and showed that the metabolic profile of seemingly macroscopically normal mucosa was indistinguishable from that of inflamed colonic tissue. This

![Fig. 3. Multivariate data analysis.](image)
improving mucosal healing modiﬁcation of the data set and is helpful for identifying inherent clusters and separations within the data set and possible outliers. Subsequent supervised analysis methods, such as partial least squares/projection to latent structures discriminant analysis (PLS-DA) and orthogonal signal correction projections to latent structures discriminant analysis (O-PLS-DA), are necessary to extract important biomarkers. In PCA, only x data are considered, whereas partial least squares are an extension of PCA and considers both x and y data sets.

Here the data set can be class membership (PLS-DA) or other biological descriptions (PLS). It is regarded as a supervised modeling method when the multivariate data analysis considers the y data set. The supervised modeling satisfies dimensional reduction (PCA) and correlation with the response matrix (y data) at the same time, generating metabolic information relating to biological events of interest. The purpose of applying orthogonal signal correction is to remove data that are unrelated to the response matrix, such as instrument instability or other irrelevant confounding factors. However, this supervised method increases the risk of overﬁtting the model, and therefore subsequent model validation procedures are essential when performing supervised data analyses.

### Box 1
Multivariate data analysis.

**Principal component analysis (PCA)** is an unsupervised data analysis method that requires two conditions: (1) each principal component (PC) is the best explanation of the original variables (x data) in the data set, and (2) each PC is orthogonal to every other PC. Data analysis results are visualized using the PC score and loadings plots. PCA gives an overview of the structure of the data set and is helpful for identifying inherent clusters and separations within the data set and possible outliers. Subsequent supervised analysis methods, such as partial least squares/projection to latent structures discriminant analysis (PLS-DA) and orthogonal signal correction projections to latent structures discriminant analysis (O-PLS-DA), are necessary to extract important biomarkers. In PCA, only x data are considered, whereas partial least squares are an extension of PCA and considers both x and y data sets.

Here the data set can be class membership (PLS-DA) or other biological descriptions (PLS). It is regarded as a supervised modeling method when the multivariate data analysis considers the y data set. The supervised modeling satisfies dimensional reduction (PCA) and correlation with the response matrix (y data) at the same time, generating metabolic information relating to biological events of interest. The purpose of applying orthogonal signal correction is to remove data that are unrelated to the response matrix, such as instrument instability or other irrelevant confounding factors. However, this supervised method increases the risk of overﬁtting the model, and therefore subsequent model validation procedures are essential when performing supervised data analyses.

---

observation suggests that involvement of the colonic mucosa is far more extensive at the molecular level and might represent a preclinical inﬂammation of more oral, i.e., proximal, extension of lesions over time. These studies consequently raise two interesting questions: can metabonomics be used to predict imminent ﬂares and thus support proactive personalized medical care, and moreover, is metabonomics-based remission an actual concept and a new potential treatment target? Indeed, integrated metabonomic and transcriptomic analyses have identiﬁed quiescent UC as a distinct phenotype as compared with control individuals [40,41]. Intriguingly, these integrated classiﬁcation models also differentiate between early and late disease onset (above or below 25 years of age) and moreover they differentiate between patients with and without glucocorticoid dependency. This is of utmost importance because early identiﬁcation of patients with glucocorticoid dependency might lead to more optimized and personalized treatment in terms of timely introduction of immunomodulators and/or biologics.

These phenotypic ﬁndings have also been observed with MS-based lipidomic [21] (i.e., a subset of the metabolome) and metabonomic studies [20] and may discriminate between patients with ﬂares of UC, patients with quiescent UC, and control individuals in multivariate modeling. Here 220 different lipids and 177 metabolites were identiﬁed, respectively, but the highest signiﬁcant variation was observed within the sphingolipids, phosphatidylcholine (PC), lysophosphatidylcholine (LPC), and a range of amino acids. The changes were also registered in patients with quiescent UC, albeit to a lesser extent, but correlated with previous MS-based lipidomic studies on mucus from patients with UC and CD and control individuals, in whom reduced levels of PC and LPC in both ﬂaring and quiescent UC, but not in CD, were found [42]. These aforementioned ﬁndings have led to a phase III placebo-controlled trial of a modiﬁed release of PC, which showed signiﬁcant improvement of the activity in mesalazine-refractory UC [43]. The low levels of PC and LPC in quiescent disease also indicate that PC treatment might be beneﬁcial for sustained clinical remission, but this needs to be elucidated.

In recent years it has gradually become evident that the main risk factors for disease ﬂares, coelectyly, and colorectal cancer in UC are sustained wound formation and inﬂammation and that medication improving mucosal healing modiﬁes the disease course favorably [44]. Thus, histologic remission has become the new treatment target. However, with the identiﬁcation of a potential metabonomic remission in UC, large-scale prospective studies based on metabonomics and intestinal biopsies are warranted to validate whether metabonomic remission is associated with an even better long-term state of remission and consequently a disease-modifying course [45].

### 3.2. Serum metabonomics and a proatherogenic lipid proﬁle

Williams et al. [46] were the ﬁrst to demonstrate signiﬁcant differences in the metabolic proﬁles of serum in patients with quiescent UC and CD and control individuals. The major discriminatory metabolites were low levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), unsaturated lipids, choline, alanine, acetate, and isoleucine, whereas very low-density lipoprotein (VLDL), glucose, lactate, and N-acetylglycoprotein were increased. The patients were evaluated based on clinical activity scores, that is, the Simple Clinical Colitis Activity Index (SCCAI) [47] or the Harvey Bradshaw Index (HBI) [48] for UC and CD, respectively. Subclinical inﬂammatory processes might explain the observed differences at clinically quiescent disease, because no endoscopic or indirect measures of inﬂammation were provided (e.g., increased levels of C-reactive protein or calprotectin). All subsequent and methodologically similar studies, that is, NMR-based studies, have been unable to differentiate between patients with UC and CD [49–53], although several of the metabolic perturbations have been replicated, albeit in patients with ﬂaring IBD. Especially the proatherogenic lipid proﬁle with increased VLDL [46,51,53] and decreased HDL [46,53] is repeatedly found in patients with active IBD and seems to be the consequence of increased transit times, malabsorption, and the inﬂammatory setting. In this environment, tumor necrosis factor alpha (TNF-α) stimulates the release of free fatty acids from adipocytes and the production of triglycerides in the liver and inhibits the hydrolysis of triglycerides in VLDL, leading to an increase in VLDL and decrease in HDL [54]. Moreover, in a longitudinal study monitoring the metabolic trajectory during induction treatment of IBD patients with infliximab, the proatherogenic lipid proﬁle was ameliorated in the patients with IBD brought into remission, which was not the case for nonresponders [53]. This is of immediate clinical importance because an increased incidence of cardiovascular morbidity is found among patients with IBD [55,56], making patients with frequent ﬂares or chronically active disease potential candidates for concomitant statin treatment and lifestyle intervention. This kind of intervention is currently not recommended in any international IBD treatment algorithms, but as the proatherogenic nature of the inﬂammation is further underlined by the low levels of choline [46,51] and glycerophosphocholine (GPC) [51,53] and an increased level of trimethylamine-N-oxide (TMAO) [57], all of which are correlated with cardiovascular disease [58,59] this might change in a foreseeable future.

### 3.3. Serum metabonomics and fatigued quiescent IBD patients

Fatigue is one of the most disabling [60] and prevalent extraintestinal manifestations of IBD and is registered in 80% of patients with active IBD and 50% of patients with quiescent IBD [61]. Despite these numbers, surprisingly little is known about fatigue in IBD, and the etiology still remains elusive. However, a recent exploratory lipidomic study associated fatigue and clinically quiescent IBD in patients with signiﬁcantly decreased levels of PCs, LPCs, plasmanyls, sphingomyelins, phosphatidylethanolamines (PAs), phosphatidylinositols (P1s), phosphatidylserines (Pss), and eicosanoids [62]. Furthermore, a prevailing gut–brain-axis link hypothesis has animated a prospective multivariate study including quiescent IBD patients with and without fatigue; fatigued quiescent IBD patients were identiﬁed with lower biodiversity and a reduced abundance of Faecalibacterium, Ruminococcus, and Alistipes and a higher abundance of Coprobacillus, which correlated with decreased levels of tryptophan and branched-chain amino acids (BCAAs) when compared with nonfatigued patients with quiescent IBD [63]. The proteome data revealed no signiﬁcant differences in inﬂammatory cytokines (e.g., interleukin 6 [IL-6]) and thus
no overt systemic inflammation. The authors consequently speculate whether a local proinflammatory environment exists in the intestines that is associated with fatigue despite clinical and endoscopic remission. This is in line with the previously described state of metabonomic remission, and whether the imbalance in tryptophan and BCAs might play a pivotal part in the pathophysiology of fatigue in patients with quiescent IBD because these metabolites are known to modify mood and depressive symptoms [64,65]. This classical hypothesis-generating metabonomic study obviously merits further investigation because these findings have relevance beyond IBD owing to the high prevalence of fatigue throughout a wide range of chronic inflammatory diseases. A placebo-controlled crossover trial was designed to determine the effect of oral 5-hydroxytryptophan on fatigue in patients with IBD is currently being performed and results are eagerly awaited (ClinicalTrials.gov; identifier: NCT03574948).

4. IBD metabonomics predicts disease course

Prediction of disease course in terms of progression and severity is essential to proactive precision medicine. Today the disease course is monitored by clinical scores, imaging, endoscopy, calprotectin, and blood samples resulting in active rather than proactive management, which calls for identification of predictive biomarkers.

Histidine is consistently reported at low levels in patients with IBD, which was also noted by Hisamatsu et al. [66], who in a prospective study of patients with quiescent UC and among 19 investigated metabolites solely identified low levels of plasma histidine to be predictive of relapse within a 1-year period. In this study, remission was based only on clinical scores, and subclinical inflammation might explain the low levels of histidine. However, Probert et al. [67] identified plasma metabolic profiles capable of discriminating between high and low endoscopic activity and corresponding histologic severity, demonstrating for the first time that serum-based metabonomics can distinguish between mild and severe active UC. The patients were followed prospectively, and a distinct baseline metabolic profile was identified that predicted worsening of symptoms within a period of 6 months (accuracy 74% ± 4%), and again histidine, at low levels, was found to be one of the major predictive metabolites. Kohashi et al. [68] identified 114 metabolites in the sera from UC patients and control individuals. Based on test and validation cohorts (60 UC patients and 60 control individuals in each) and a predefined selection strategy for metabolites holding differential power, a diagnostic model that differentiated between UC and CD was created based on four metabolites: oxalate, 3-hydroxybutyrate, ribulose, and 1,6-anhydroglucose. Applying the same strategy, a UC assessment model was also established that correlated with the clinical activity score. This model contained two metabolites, p-hydroxybenzoic acid and histidine, and again histidine was found at low levels, and in an inverse correlation with the clinical activity score. In a subsequent prospective monitoring study of patients with UC, patients in remission with succeeding flares had a concomitant increase in the assessment model’s value and patients with active disease had a reduction of the value during treatment, suggesting that this model could be applied as a monitoring tool. Thus Kohashi et al. [68] developed potential diagnostic and assessment models for monitoring UC, but it is important to note that treatment with sulfasalazine was found to be positively correlated with worsening of symptoms within a period of 6 months (accuracy 74%). However, the underlaying microbiologic processes, mechanisms of action, and predictors of outcome still remain unknown. An exploratory study applied a metabonomics approach and revealed greater biodiversity before and after FMT in patients achieving remission, with enrichment of Eubacterium hallii and R. inulinivorans and increased levels of SCFAs, indicating that FMT might be used as a biomarker for predicting disease course, but a major prospective IBD cohort study including clinical, endoscopic, and histologic scores is required to validate its potential.

Prediction of disease course also appears achievable using a multianomics approach on serum samples because it seems possible to identify otherwise quiescent IBD patients who are not in histologic remission and consequently at risk of an imminent flare. An established model of four metabolites, propionyl-L-carnitine, carnitine, sarcosine, and sorbitol, combined with three proteins, IL-10, giall cell line–derived neurotrophic factor, and the T-cell surface CD8 alpha chain, was found to be predictive of relapse within 2 years [22]. An independent validation of these results would translate into an applicable clinical tool and empower proactive treatment strategies.

5. IBD metabonomics predicts treatment response

5.1. Metabonomics predicts response to biologic therapy

A bile acid dysmetabolism characterized by defective deconjugation, transformation, and desulfation has repeatedly been documented in IBD and associated with dysbiosis [11,17,23,69,70]. This results in a relative overabundance of primary and sulfated bile acids and a dysbiosis-induced secondary bile acid deficiency that promotes colonic inflammation. The apparent bile acid dysmetabolism combined with a disturbed lipid profile has been shown to predict response to TNF inhibitor treatment because primary bile acids and increased levels of especially sphingomyelin in feces have been associated with nonresponders [23]. Similarly, butyrate and substrates involved in butyrate synthesis (e.g., acetaldehyde) have been identified as predictive metabolites of clinical remission following biologic therapy in a metabolonomics-based (i.e., microbiome) gene-sequencing and fecal metabolic profiling in silico prediction study [71]. Prior to treatment, a clear dysbiosis was found with reduced biodiversity and a reduction in individual phylotypes such as Coprococcus and Roseburia inulinivorans (short-chain fatty acid [SCFA] producers). After treatment, these differences were almost nonexistent in both responders and nonresponders. The fecal metabolic profile, in contrast, remained significantly disrupted in nonresponders, whereas responders experienced an increase especially in butyric acid (an SCFA). Importantly, already at baseline nonresponders had a more profoundly affected metabolic profile, making it possible to predict drug response. This study subsequently validated the results in an IBD cohort and confirmed that metabolic profiling of fecal samples has the potential to identify patients likely to achieve clinical remission with biologic treatment. Thus fecal-based metabolic profiles of bile acids, lipids, and SCFAs are already available for clinical testing and validation.

Serum-based metabonomics has identified lipid profiles with increased levels of phosphocholine, ceramide, sphingomyelin, and triglycerides in nonresponders to TNF inhibitors, demonstrating that a potential pharmacodynamic explanation for the primary driver of inflammation in anti-TNF nonresponders might be lipid based [23]. Thus, it is likely that the genesis of the dominant inflammatory process in patients with IBD correlates with different metabolic phenotypes in which some are driven by TNF and others are driven by lipid. If this kind of a priori knowledge can be made available in the clinical setting, it would undoubtedly have a significant impact on personalized medicine when choosing between a TNF inhibitor and other regimens from the therapeutic armamentarium.

5.2. Fecal metabonomics predicts fecal microbiota transplantation response

A few studies have indicated that FMT in patients with UC has the ability to induce remission [72–74]. However, the underlaying microbial processes, mechanisms of action, and predictors of outcome still remain unknown. An exploratory study applied a metabonomics approach and revealed greater biodiversity before and after FMT in patients achieving remission, with enrichment of Eubacterium hallii and R. inulinivorans and increased levels of SCFAs, biosynthesis, and secondary bile acids in treated versus nontreated patients [24], which is in line with changes observed in anti-TNF responders and nonresponders. An essentially similar pediatric study of FMT in patients with UC combining 16S rRNA gene sequencing and metabonomics illustrated that the gut microbial and metabolic profiles, including changes in SCFAs among patients responding to FMT, shifted toward those of the donors.
However, the metabolic profile of one patient remained stable and significantly different from those of healthy donors despite successful transfer of microbes. This patient experienced only a partial response to FMT, highlighting the fact that the response to treatment does not depend on single factors such as SCFAs or specific microbiota, but rather on an interplay among multiple factors [75]. Thus, treatment and subsequent reestablishment of the microbiota is not sufficient to achieve remission but have to be paralleled with concomitant changes in the metabolome. The mechanism of action by which FMT and biologics induce these changes is currently unknown and necessitates further investigation of the host–microbiota interaction with detailed in-depth molecular characterization of the mucosa-related microbiota and its interplay with host omics during treatment.

6. Outstanding questions and future key clinical perspectives

Is the potential metabolomics remission associated with an even better long-term state of remission compared to histological remission and consequently a disease modifying course?

The treat-to-target paradigm is currently aimed at mucosal healing, however, increasing evidence support deep mucosal healing with histological remission as the next target. With the existence of a potential metabolomics remission in IBD a future treatment target might be set at the molecular level to achieve better long-term outcomes.

Should IBD patients with chronic active disease or frequent flares be treated with lifestyle intervention and statins due to a proatherogenic lipid profile?

A proatherogenic serum lipid profile characterizes patients with active IBD and correlates with an increased incidence of cardiovascular morbidity. Achieving a state of remission ameliorates the proatherogenic profile underlining the importance of treat-to-target and concomitant statin treatment and lifestyle intervention in patients with frequent flares or chronic activity. The latter is not included in any international IBD treatment guidelines, but with the current knowledge this might change in a foreseeable future.

Is it possible to treat fatigue in quiescent IBD patients?

Fatigue is the most prominent extraintestinal manifestation in IBD with up to 50% of patients in remission being affected, yet little is known about the cause. Metabonomics has, however, identified tryptophane and branched chain amino acids to be potential treatment strategies and current clinical trials with tryptophane is ongoing.

Is histidine and integrated omics able to predict eminent flares prior to manifest clinical symptoms enabling precision medicine?

Predicting disease course is the very essence of precision medicine. Serum-based metabolomics seem to have identified histidine and an integrated metabolomics and proteomics profile able to predict eminent flares enabling proactive medical care if validated in large prospective IBD cohorts.

Can fecal metabolomics predict response to biological and FMT treatment?

Fecal bile acids, lipids, and SCFA profiles have been shown to predict response to biologics and FMT facilitating a priori identification of appropriate candidates. If validated, this will have a tremendous impact on future treatment strategies.

7. Conclusions

This review has provided up-to-date knowledge on the workflow and commonly applied analytical techniques in IBD metabolomics and has shown metabolomics to be a very promising clinical tool for predictive modeling in terms of phenotyping, imminent flares, and response to treatment. Thus, the proatherogenic lipid profile in active IBD and tryptophan deficits in the fatigued phenotype are readily converted into clinically applicable treatment strategies. Moreover, the identified concept of metabolomic remission might in the foreseeable future change our treatment target for patients with UC and potentially alter the natural history of the disease. Finally, real world precision medicine is one step closer in IBD because of the identified predictive metabolites and omics profiles. We anticipate that future standardized protocols, affordable instruments, and user-friendly analysis platforms will become more widely available, and metabolomics will consequently play an increasingly important role alongside other diagnostic and prognostic tools in a clinical setting and provide us with personalized medicine, as well as clues for new therapeutic avenues.

Search strategy

Data for this Review were identified by searches of MEDLINE, Current Contents, PubMed, and references from relevant articles using the search terms “metabolomics”, “metabonomics”, inflammatory bowel disease”, “ulcerative colitis” and “Crohn’s disease”. Only articles published in English between 1980 and 2021 were included.

Contributors

Conceptualisation: JTB, OHN; literature search: JTB, OHN; original draft: JTB; writing: JTB, YLW, JBS, OHN; figures and visualization: JTB; review and editing: JTB, YLW, JBS, OHN

Declaration of Competing Interest

The authors have no interests to declare.

Acknowledgements

The authors acknowledge the financial support from Aase og Ejnar Danielsens Fond, Civilingeniør Frode V. Nygaard and Hustrus Fond, Aage og Johanne Louis-Hansens Fond, Colitis-Crohn Foreningen, and Frimodt-Heineke Fonden. The funders were not involved in the study in any way.

References

[1] Zhao M, Gönczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohn’s Colitis 2021. doi: 10.1093/ccc-jcc/jjab029. In press.

[2] Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med 2020;383:2652–64.

[3] Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Prim 2020:6:74.

[4] Roda G, Chien Ng SJ, Kötze PG, et al. Crohn’s disease. Nat Rev Dis Prim 2020:6:22.

[5] Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative colitis and Crohn’s disease have similar burden and goals for treatment. Clin Gastroenterol Hepatol 2020;18:14–23.

[6] Nicholson JK, Lindon JC, Holmes E. Metabonomics”: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistic analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181–9.

[7] Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:223–37.

[8] Van Malderen K, De Winter BY, De Man JG, De Schepper HU, Lamote K. Volatomics in inflammatory bowel disease and irritable bowel syndrome. ElBioMedicine 2020;54:102725.

[9] Gallagher K, Catesson A, Griffin JL, Holmes E, Williams HRT. Metabolomic analysis in inflammatory bowel disease: a systematic review. J Crohn’s Colitis 2021;15:813–26.

[10] Bausert C, Gisbert-Ferrán J, Cosín-Roger J. Metabolomics as a promising resource identifying potential biomarkers for inflammatory bowel disease. J Clin Med 2021;10:622.

[11] Franciosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 2019;4:293–305.

[12] Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017;66:963–71.

[13] Santoro ML, Piras C, Murgia A, et al. Cross sectional evaluation of the gut-microbiome-metabolome axis in an Italian cohort of IBD patients. Sci Rep 2017;7:9523.

[14] Bjerrum JT, Wang Y, Hao F, et al. Metabolomics of human fecal extracts characterise ulcerative colitis, Crohn’s disease and healthy individuals. Metabolomics 2015;11:122–33.
Bjerum JT, Nielsen OH. Metabolomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteom 2010;73:138–49.

Bjerum JT, Nielsen OH, Flentje T, et al. Metabolomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteom 2010;73:138–49.

Dal Buono A, Roda G, Aragona G, et al. Phosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by high-resolution magic-angle spinning 1H NMR spectroscopy of liver tissues. Anal Biochem 2003;323:26–32.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.

Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: a unique molecular phenotype for ulcerative colitis. J Proteome Res 2010;9:1023–8.